CMS Proposes Medicare Advantage Directory Accuracy Scores, Part D PBM Limits And $0 Generic Copay

The proposed rule implements three sections of the Consolidated Appropriations Act, 2026, with a 60-day comment period after publication.

Share
CMS Proposes Medicare Advantage Directory Accuracy Scores, Part D PBM Limits And $0 Generic Copay

The Centers for Medicare & Medicaid Services (CMS) on Friday issued a proposed rule implementing three sections of the Consolidated Appropriations Act of 2026: provider directory accuracy, pharmacy benefit manager (PBM) limits in Part D, and a $0 generic copayment for some low-income enrollees. It is a proposal, not a final rule, and it can change after public comment.

What the proposed rule would do

The rule, labeled CMS-4214-P, would cut the Part D generic drug copayment from $1 to $0 for full-benefit dual eligible people (those covered by both Medicare and Medicaid) at or below 100% of the Federal Poverty Level. It would take effect for plan years starting Jan. 1, 2028. CMS describes this as a conforming change mandated by section 6219 of the law.

On provider directories, CMS proposes to codify the REAL Health Providers Act (section 6220). It would set verification and accuracy requirements for Medicare Advantage organizations beginning in contract year 2028.

The proposed requirements cover directory verification and maintenance standards, annual accuracy analysis and reporting, public reporting of accuracy scores, and cost-sharing protections for enrollees who rely on inaccurate directory information.

For contract year 2029, CMS would have to publicly display directory accuracy scores in a machine-readable format. Medicare Advantage organizations would have to display those scores prominently in their directories.

The PBM proposals

Section 6224 sets Part D requirements for PBMs and their affiliates. CMS's proposals cover limits on the remuneration PBMs may receive in connection with Part D drug use, and data reporting to prescription drug plan sponsors and to CMS.

They also cover transparency in PBM price guarantee arrangements, and PBM disclosure to plan sponsors of the terms of certain agreements with drug manufacturers.

CMS also proposes to define key terms and set compliance and enforcement mechanisms. These include disgorgement, meaning repayment, of funds to CMS for violations of the remuneration requirements.

What to watch

The proposed rule will be open for public comment for 60 days after it is published in the Federal Register. The material does not give a publication date, so the comment deadline is not yet set.

The underlying law was signed on February 3, 2026.

The 60-day comment clock starts only when the rule appears in the Federal Register, and the copayment change would not apply until plan years starting Jan. 1, 2028.

Sources